Xeris Biopharma Holdings, Inc. (XERS)
Largest Insider Buys in Sector
XERS Stock Price History Chart
XERS Stock Performance
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's …
Insider Activity of Xeris Biopharma Holdings, Inc.
Over the last 12 months, insiders at Xeris Biopharma Holdings, Inc. have bought $50,413 and sold $0 worth of Xeris Biopharma Holdings, Inc. stock.
On average, over the past 5 years, insiders at Xeris Biopharma Holdings, Inc. have bought $461,263 and sold $137,490 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schmid John P. (director) — $80,630. SHERMAN JEFFREY W (director) — $10,098.
The last purchase of 4,515 shares for transaction amount of $10,147 was made by Schmid John P. (director) on 2024‑08‑12.
List of Insider Buy and Sell Transactions, Xeris Biopharma Holdings, Inc.
| 2024-08-12 | director | 4,515 0.003% | $2.25 | $10,147 | +29.33% | |||
| 2024-08-09 | director | 4,285 0.0029% | $2.37 | $10,134 | +25.22% | |||
| 2024-05-10 | director | 5,400 0.004% | $1.91 | $10,314 | +50.85% | |||
| 2024-03-14 | director | 4,500 0.0032% | $2.16 | $9,720 | +8.92% | |||
| 2023-11-27 | director | 5,400 0.004% | $1.87 | $10,098 | +29.35% | |||
| 2023-11-20 | See Remarks | 28,000 0.0218% | $1.95 | $54,600 | +30.10% | |||
| 2023-11-20 | director | 5,410 0.004% | $1.84 | $9,954 | +30.10% | |||
| 2023-11-17 | See Remarks | 30,769 0.0206% | $1.64 | $50,400 | +35.24% | |||
| 2023-11-16 | director | 6,500 0.0045% | $1.51 | $9,815 | +49.21% | |||
| 2023-11-14 | director | 6,370 0.0047% | $1.58 | $10,058 | +51.94% | |||
| 2023-08-09 | See Remarks | 10,000 0.0073% | $2.38 | $23,794 | -10.64% | |||
| 2022-12-13 | See Remarks | 20,000 0.0152% | $1.45 | $29,000 | +34.75% | |||
| 2022-05-12 | See Remarks | 100,000 0.0681% | $1.40 | $140,380 | +0.66% | |||
| 2022-02-22 | Sale | Chief Scientific Officer | 11,228 0.0085% | $2.42 | $27,158 | -32.35% | ||
| 2021-11-15 | See Remarks | 20,000 0.0151% | $2.28 | $45,664 | -17.14% | |||
| 2021-11-12 | See Remarks | 60,000 0.0484% | $2.10 | $126,000 | -2.80% | |||
| 2021-11-11 | See Remarks | 200,000 0.1644% | $2.08 | $415,760 | 0.00% | |||
| 2021-11-11 | See Remarks | 40,000 0.033% | $2.09 | $83,500 | 0.00% | |||
| 2021-11-10 | See Remarks | 25,000 0.0216% | $2.00 | $49,918 | +9.47% | |||
| 2021-04-12 | Sale | Chief Scientific Officer | 10,000 0.0156% | $4.07 | $40,725 | -34.99% |
Insider Historical Profitability
| Schmid John P. | director | 25200 0.0169% | $3.09 | 5 | 0 | |
| SHERMAN JEFFREY W | director | 5400 0.0036% | $3.09 | 1 | 0 | |
| Redmile Group, LLC | 10 percent owner | 3000642 2.0128% | $3.09 | 2 | 0 | <0.0001% |
| Edick Paul R | See Remarks | 2288064 1.5348% | $3.09 | 10 | 0 | +2.62% |
| Palmetto Partners, Ltd. | 10 percent owner | 2110061 1.4154% | $3.09 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $22.01M | 6.72 | 9.96M | -0.51% | -$112,455.84 | <0.0001 | |
| The Vanguard Group | $16.81M | 5.13 | 7.61M | +7.34% | +$1.15M | <0.0001 | |
| Caxton Corp | $11.3M | 3.45 | 5.11M | -9.37% | -$1.17M | 64.39 | |
| Bioimpact Capital Llc | $9.21M | 2.81 | 4.17M | +8.3% | +$705,573.43 | 1.49 | |
| State Street | $7.11M | 2.17 | 3.22M | +18.02% | +$1.08M | <0.0001 |